Novavax, Inc. (NVAX) vs Sarepta Therapeutics, Inc. (SRPT)
A side-by-side comparison of Novavax, Inc. and Sarepta Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NVAX
Novavax, Inc.
$11.09HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
SRPT
Sarepta Therapeutics, Inc.
$17.16HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — NVAX vs SRPT
growth of $100 · dividends reinvested · last 10yNVAX -68.6% (-10.9%/yr)SRPT -67.4% (-10.6%/yr)SRPT compounded faster over this window
NVAX SRPT
NVAX vs SRPT: by the numbers
- •NVAX is the larger company ($1.82B vs $1.81B market cap).
- •Both run net losses; SRPT's is the smaller (-6.93% vs -59.87% net margin).
- •NVAX grew revenue faster over the past five years (118.86% vs 26.90% CAGR).
Metrics side by side
Valuation
| Metric | NVAX | SRPT |
|---|---|---|
| Forward P/E | N/A | 5.34 |
| P/S ratio | 4.41 | 0.92 |
| P/B ratio | N/A | 1.19 |
Profitability
| Metric | NVAX | SRPT |
|---|---|---|
| Gross margin | 93.67% | 58.56% |
| Operating margin | 50.14% | -29.92% |
| Net margin | -59.87% | -6.93% |
| ROE | N/A | -8.95% |
| ROIC | -36.37% | -5.33% |
Growth (annualized)
| Metric | NVAX | SRPT |
|---|---|---|
| Revenue CAGR (5Y) | 118.86% | 26.90% |
| Total return CAGR (5Y) | -40.61% | -28.74% |
Frequently asked
- Which has grown faster, NVAX or SRPT?
- Over the past five years, NVAX grew revenue faster — NVAX at a 118.86% CAGR versus SRPT at 26.90%.
- How have NVAX and SRPT total returns compared?
- Over the past 10 years, NVAX delivered -10.98% and SRPT delivered -11.94% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Novavax ROESarepta Therapeutics ROENovavax operating marginSarepta Therapeutics operating marginNovavax revenue growthSarepta Therapeutics revenue growthNovavax free cash flowSarepta Therapeutics free cash flow
Novavax & Sarepta Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.